Vaccine Evaluation Centre
Welcome,         Profile    Billing    Logout  
 10 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halperin, Scott A
NCT04526990: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Completed
3
44247
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo
CanSino Biologics Inc., Beijing Institute of Biotechnology
COVID-19
08/21
10/22
NCT03031912 / 2016-004853-34: African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

Active, not recruiting
2
250
Canada
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline
Cecile Tremblay, Merck Sharp & Dohme LLC, International Development Research Centre, Canada, Dalhousie University, Université de Montréal, Coalition for Epidemic Preparedness Innovations
Ebola
10/24
02/25
NCT05136599: Establishing a Controlled Human Infection Model of Bordetella Pertussis

Active, not recruiting
1
79
Canada
Bordetella pertussis D420
Dalhousie University, National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control and Prevention, Vanderbilt University Medical Center
Pertussis
03/25
03/25
NCT06465420: A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype a Vaccine

Active, not recruiting
1
30
Canada
Haemophilus influenzae type a (Hia) glycoconjugate vaccine
InventVacc Biologicals Inc., Hia Consortium
Haemophilus Influenzae Meningitis, Invasive Haemophilus Influenzae Disease
10/24
03/25
NCT05991427: A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Completed
1
65
Canada
Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant, Adjuvanted (Shingrix), ChAdOx1-VZV, Shingrix, IH ChAdOx1-VZV, IH saline
CanSino Biologics Inc.
Herpes Zoster
11/24
11/24
McNeil, Shelly
NCT05136599: Establishing a Controlled Human Infection Model of Bordetella Pertussis

Active, not recruiting
1
79
Canada
Bordetella pertussis D420
Dalhousie University, National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control and Prevention, Vanderbilt University Medical Center
Pertussis
03/25
03/25
Langley, Joanne
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
MOSAIC, NCT04894435: Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

Active, not recruiting
2
669
Canada
mRNA-1273 SARS-CoV-2 vaccine, COVID-19 Vaccine Moderna, Spikevax, BNT162b2, Pfizer-BioNTech COVID-19 Vaccine, Comirnaty, ChAdOx1-S [recombinant], Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria, 0, 28 day schedule, 0, 112 day schedule, Covifenz, Medicago COVID-19 vaccine
Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
11/24
02/25
NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
1/2
1256
Europe, Canada, US, RoW
Flu mRNA, GSK4382276A, Control 1, Control 2
GlaxoSmithKline, CureVac
Influenza, Human
07/24
08/24
NCT04702178: A Clinical Trial of COVAC-2 in Healthy Adults

Completed
1
61
Canada
COVAC-2, Saline Placebo
University of Saskatchewan, Government of Canada, Government of Saskatchewan, Vaccine Formulation Institute (VFI), Seppic
Severe Acute Respiratory Syndrome Coronavirus 2
11/22
11/22
NCT04773665: Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Completed
1
114
Canada
VBI-2902a, Placebo, VBI-2905a
VBI Vaccines Inc.
Covid19
11/22
11/22
IVT PCV-25, NCT05540028: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Completed
1
65
Canada
IVT PCV-25, PCV 20
Inventprise Inc., Canadian Center for Vaccinology, Vaccine Evaluation Center, Canada, PATH
Pneumococcal Vaccines
07/23
07/23
NCT05226702: Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.

Completed
1
60
Canada
COVAC-2, Saline Placebo
University of Saskatchewan, Government of Canada, Government of Saskatchewan, Vaccine Formulation Institute (VFI), Seppic
Double Vaccinated for COVID-19 (For Phase 1 of the Study), Acute Respiratory Syndrome Coronavirus 2 (For Phase 2 Exploratory Group)
11/23
11/23
NCT05136599: Establishing a Controlled Human Infection Model of Bordetella Pertussis

Active, not recruiting
1
79
Canada
Bordetella pertussis D420
Dalhousie University, National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control and Prevention, Vanderbilt University Medical Center
Pertussis
03/25
03/25
NCT05548439: Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a

Active, not recruiting
1
103
Canada
VBI-2901a
VBI Vaccines Inc.
COVID-19, Coronavirus Infections
02/24
02/24
NCT06465420: A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype a Vaccine

Active, not recruiting
1
30
Canada
Haemophilus influenzae type a (Hia) glycoconjugate vaccine
InventVacc Biologicals Inc., Hia Consortium
Haemophilus Influenzae Meningitis, Invasive Haemophilus Influenzae Disease
10/24
03/25
Dionne, Marc
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
MOSAIC, NCT04894435: Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

Active, not recruiting
2
669
Canada
mRNA-1273 SARS-CoV-2 vaccine, COVID-19 Vaccine Moderna, Spikevax, BNT162b2, Pfizer-BioNTech COVID-19 Vaccine, Comirnaty, ChAdOx1-S [recombinant], Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria, 0, 28 day schedule, 0, 112 day schedule, Covifenz, Medicago COVID-19 vaccine
Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
11/24
02/25
NCT05548439: Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a

Active, not recruiting
1
103
Canada
VBI-2901a
VBI Vaccines Inc.
COVID-19, Coronavirus Infections
02/24
02/24
Kollman, Tobias
No trials found

Download Options